We are live on ! Find out more
Baillie Gifford & Co

Baillie Gifford & Co Portfolio holdings

AUM $110B
1-Year Est. Return 4.8%
 

Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.

This Fund
S&P 500
This Quarter Est. Return
+7.52%
1 Year Est. Return
+4.8%
3 Year Est. Return
+123.53%
5 Year Est. Return
+125.55%
10 Year Est. Return
+1,754.37%
AUM
$96B
AUM Growth
-$1.03B
Cap. Flow
-$1.11B
Cap. Flow %
-1.16%
Top 10 Hldgs %
36.39%
Holding
500
New
14
Increased
150
Reduced
126
Closed
12

Top Buys

Rank Stock Value
1
TEAM icon
Atlassian
TEAM
+$350M
2
NVDA icon
NVIDIA
NVDA
+$308M
3
MELI icon
Mercado Libre
MELI
+$305M
4
RBLX icon
Roblox
RBLX
+$300M
5
NIO icon
NIO
NIO
+$280M

Sector Composition

Rank Sector Weight
1 Healthcare 27.94%
2 Consumer Discretionary 24.48%
3 Technology 18.24%
4 Communication Services 10.28%
5 Financials 7.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BB icon
426
BlackBerry
BB
$5.26B
$7.93K ﹤0.01%
2,434
OM icon
427
Outset Medical
OM
$90.8M
$7.9K ﹤0.01%
20
SGMO
428
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$7.88K ﹤0.01%
2,510
MNTV
429
DELISTED
Momentive Global Inc. Common Stock
MNTV
$7.67K ﹤0.01%
1,095
AMD icon
430
Advanced Micro Devices
AMD
$789B
$7.64K ﹤0.01%
118
KYNB
431
Kyntra Bio
KYNB
$29.4M
$7.48K ﹤0.01%
19
HI
432
DELISTED
Hillenbrand
HI
$7.25K ﹤0.01%
170
WSM icon
433
Williams-Sonoma
WSM
$29.6B
$7.24K ﹤0.01%
126
ZYXI
434
DELISTED
Zynex
ZYXI
$6.69K ﹤0.01%
481
FOLD
435
DELISTED
Amicus Therapeutics
FOLD
$6.57K ﹤0.01%
538
RIO icon
436
Rio Tinto
RIO
$164B
$6.55K ﹤0.01%
92
+32
+53% +$2.01K
NVRO
437
DELISTED
NEVRO CORP.
NVRO
$6.1K ﹤0.01%
154
CRH icon
438
CRH
CRH
$66.8B
$6.05K ﹤0.01%
152
+52
+52% +$1.95K
BLUE
439
DELISTED
bluebird bio
BLUE
$5.95K ﹤0.01%
43
SUMO
440
DELISTED
Sumo Logic, Inc. Common Stock
SUMO
$5.88K ﹤0.01%
726
MATV icon
441
Mativ Holdings
MATV
$711M
$5.54K ﹤0.01%
265
RARE icon
442
Ultragenyx Pharmaceutical
RARE
$2.55B
$5.33K ﹤0.01%
115
CERS icon
443
Cerus
CERS
$474M
$5.33K ﹤0.01%
1,459
CSTL icon
444
Castle Biosciences
CSTL
$979M
$5.3K ﹤0.01%
225
AGIO icon
445
Agios Pharmaceuticals
AGIO
$1.93B
$5.22K ﹤0.01%
186
ATEX icon
446
Anterix
ATEX
$1.94B
$5.21K ﹤0.01%
162
OXM icon
447
Oxford Industries
OXM
$552M
$5.13K ﹤0.01%
55
ACMR icon
448
ACM Research
ACMR
$5.79B
$5.09K ﹤0.01%
660
XPER icon
449
Xperi
XPER
$348M
$4.99K ﹤0.01%
+579
New +$6.63K
LASR icon
450
nLIGHT
LASR
$3.17B
$4.75K ﹤0.01%
468

Similar funds

Baillie Gifford & Co's Q4 2022 Portfolio in Review

As of Q4 2022, Baillie Gifford & Co held 500 positions worth $96B, down 1.1% from $97B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Baillie Gifford & Co's Q4 2022 filing shows 14 new, 150 increased, 126 reduced and 12 closed positions. Its largest new stake was Eaton: 1,452,086 shares worth $228M. The largest sale was Abiomed Inc, an estimated $1.21B.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Baillie Gifford & Co's largest Q4 2022 buy was Eaton: 1,452,086 shares worth $228M.
  • Baillie Gifford & Co added most to Atlassian in Q4 2022, an estimated $350M increase.
  • Baillie Gifford & Co's biggest Q4 2022 reduction was Abiomed Inc, cutting an estimated $1.21B.
  • Baillie Gifford & Co fully exited Li Auto in Q4 2022, selling an estimated $134M.
  • Baillie Gifford & Co's ten largest holdings make up 36% of its $96B portfolio in Q4 2022.
  • Baillie Gifford & Co opened 14 new positions and closed 12 in Q4 2022.
  • Baillie Gifford & Co's portfolio value fell 1.1% quarter-over-quarter to $96B.

Based on Baillie Gifford & Co's 13F filing for Q4 2022, filed 24 Jan 2023.